KBI Biopharma is a U.S.-based subsidiary of JSR Life Sciences. The company specializes in clinical and commercial manufacturing services for mammalian, microbial, and cell therapy programs. Through a strategic consolidation with Selexis, KBI offers mammalian cell line development within nine months — the fastest service offering in the biopharmaceutical industry. KBI has multiple manufacturing sites in North Carolina and Colorado in the U.S., and a site in Switzerland.
